Discoveries

Ever wonder what about the ROI on biomedical research looks like? At the Vanderbilt University School of Medicine Basic Sciences, scientists are delivering answers—by driving discoveries that are already improving human health and paving the way for tomorrow’s treatments. This 2025–26 roundup highlights some of the year’s most exciting advances, showing the extraordinary value of sustained support for biomedical science. Read More

A new study from the laboratory of Cody Siciliano suggests that two widely used medications for alcohol use disorder—naltrexone and nalmefene—may be equally effective overall but individuals only respond to one of the two medications. The findings could help explain why clinical trials of naltrexone and nalmefene have produced conflicting results and may point toward a precision-medicine strategy for treating alcohol use disorder. Read More

Researchers identified a small molecule that improves the localization of a potassium channel frequently mislocalized and impaired in the genetic heart rhythm disorder known as long QT syndrome. The study provides proof of principle that future therapies aimed at correcting the underlying molecular defect in this potentially fatal genetic disorder could be viable. Read More

A new study reveals mechanistic underpinnings of Crohn’s disease, including some vulnerabilities within the ascending colon. This work challenges the assumption that all regions of the gut respond similarly to inflammation, argues for region-specific treatments for the disease, and highlights a potential new target for treatment within the ascending colon. Read More

The School of Medicine Basic Sciences is launching a new lecture series: “The Kairos Lectures: Research of Consequence at the Right Moment.” Read More

In a new study published in Diabetes, researchers found that prolonged treatment with the GLP-1R agonist semaglutide led to changes in feeding habits and fuel use in an animal model, offering new insights into the behavioral and metabolic adaptations that accompany weight loss, weight maintenance, and rapid weight regain after stopping treatment. Read More

Meet Jen Silverman, a Ph.D. candidate in the lab of Matthew Tyska in the Department of Cell and Developmental Biology. Read More

Hannah Collins was named the 2025 Destination Biochemistry Stanley Cohen Postdoctoral Scholar in recognition of her exceptional training, innovative research on microglial signaling, and strong potential as a future scientific leader. Joining Bruce Carter’s lab, she brings significant expertise and new perspectives to studies of the Jedi receptor in microglial function. Read More

Meet Katherine Clowes Moster, a trainee in the lab of Chuck Sanders in the Department of Biochemistry. Read More

Meet Josh Luffman, construction and project manager in the facilities, infrastructure and risk management group within the School of Medicine Basic Sciences. Read More